The problem with LDTs, home brew, is that for years FDA has exercised enforcement discretion based on the original understanding. A lab in a hospital, for example, develops a test for a specific patient and runs it in the hospital lab. FDA, correctly, said that while those test are medical devices, FDA didn't see much value in regulating them.
After years of scope creep, LDTs have become big business. As FDA tries to gain control, there has been a lot of push back for the labs.
FDA has created the, so called, four walls test. The test must be developed and run in the same lab. This means, for example, that larger companies with multiple labs in different locations, cannot share LDTs among labs.
FDA has not been enforcing this rule, as far as I know. In addition, it is not a CLIA rule, so they don't enforce it.
In the end, the practice is forbidden, but frequently occurs.
My recommendation is that you follow FDA's requirement.<o:p></o:p>
------------------------------
Dan O'Leary CQA, CQE
Swanzey NH
United States
------------------------------
Original Message:
Sent: 18-Sep-2023 11:04
From: Anonymous Member
Subject: Laboratory developed test (LDT) route
This message was posted by a user wishing to remain anonymous
Hi,
Can a CLIA clinical lab create an LDT by obtaining a protocol for a test developed as an LDT by another facility? We found this documented in a few references online but fail to understand how would you satisfy FDA's requirement of LDTs as designed, developed and manufactured within a single lab.
Thank you